What is Royalty Pharma's share buybacks?

Royalty Pharma (RPRX) reported share buybacks of $50.1M in Q1 2026.

How has Royalty Pharma's share buybacks changed year-over-year?

Royalty Pharma's share buybacks decreased by 92.9% year-over-year, from $708.78M to $50.1M.

What does share buybacks mean?

Cash used to buy back the company's own shares on the open market or through structured programs, reducing shares outstanding.

Royalty Pharma RPRX Share Buybacks

Share Buybacks at other companies

BridgeBio PharmaBBIO

$82.5M+70.9%

Rigel PharmaceuticalsRIGL

$3.74M—

Roivant SciencesROIV

$208.29M-67.9%

Innoviva, Inc.INVA

$20.25M—

AbbVieABBV

$1.49B+54.9%

ZymeworksZYME

$76.15M—

Other financials

Income statement

See full

Revenue$630.6M+11.0%

Operating income$563.0M+5.4%

Net income$294.7M+23.1%

EPS (diluted)$0.67+21.8%

Balance sheet

See full

Cash & equivalents$586.4M-46.1%

Total debt$9.0B+17.8%

Total equity$9.9B+1.6%

Total assets$19.8B+12.5%

Cash flow

See full

Operating cash flow$718.2M+20.5%

Valuation

See full

Market cap$26.58B+69.3%

Enterprise value$34.97B+51.4%

P/E32.1×+16.8×

P/S10.9×+4.1×

Profitability

See full

Operating margin65.1%-18.9pp

Net margin33.9%-14.4pp

Returns & leverage

See full

Return on equity8.4%-2.7pp

Debt / equity0.9×+0.1×

Current ratio2.7×+1.1×

Where this comes from

Reported directly by Royalty Pharma in its filing.

Tagged under the XBRL concept us-gaap:PaymentsForRepurchaseOfCommonStock.

The official record: Royalty Pharma’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Royalty Pharma's share buybacks.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Royalty Pharma's share buybacks?: Royalty Pharma (RPRX) reported share buybacks of $50.1M in Q1 2026.
How has Royalty Pharma's share buybacks changed year-over-year?: Royalty Pharma's share buybacks decreased by 92.9% year-over-year, from $708.78M to $50.1M.
What does share buybacks mean?: Cash used to buy back the company's own shares on the open market or through structured programs, reducing shares outstanding.